Suniva announced it will open a second monocrystalline silicon solar cell manufacturing facility in the United States. The ...

The company says the facility is expected to open in Q2 2027. Once it’s online, Suniva’s total US solar cell capacity will ...

First two GMP doses of rese-cel manufactured on the Cell Shuttle(TM) met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET(TM) ...

Suniva, the largest and oldest U.S. manufacturer of high-efficiency monocrystalline silicon solar cells, today announced that it has entered agreements to bring a state-of-the-art 4.5GW solar cell ...

An iPSC manufacturing strategy for cell therapies drops the cost of goods sold to about $5,000 per dose, down from $115,000 per dose for autologous therapeutics and $40,000 per dose for allogeneic ...

Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.

HEFEI, ANHUI, CHINA, January 19, 2026 /EINPresswire.com/ — The global photovoltaic (PV) industry is entering a phase defined less by headline capacity additions and ...

Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The ...

Management continues to anticipate the presentation of three-year OpRegen trial data in June 2025, with Culley expressing hope it will “provide additional conviction in our approach.” There remains no ...

In cell therapy applications, commonly employed cell purification platforms for large-scale isolation of immune or stem cells separate cells based on a single cell surface antigen. Enrichment based on ...